government work report: focus on epidemic prevention and control, speed up the research and development of new vaccines and specific drugs.
click on the blue above to pay attention to us •
On March 5, 2022, at the opening meeting of the Fifth Session of the Thirteenth National People's Congress, Premier Li Keqiang, on behalf of the State Council, delivered the 2022 government work report for China's economic and social development in 2022 under complex domestic and international situations. Goals and tasks to give instructions. In the field of medicine, it is mainly mentioned to focus on the development of vaccine research and development and control of the epidemic, in-depth innovation and development and major diseases, expand the encouragement of foreign investment, strengthen the protection of rare diseases and other aspects.
* The purple part of the following article is the original planning text.
Accelerates Development of New Vaccines and Specific Drugs
report identifies China's development goals for 2022 in terms of GDP, urban employment, consumption levels, imports and exports, and the ecological environment, and emphasizes that one of the guarantees for achieving these goals is to continue to do a good job of normalized epidemic prevention and control, which includes"increase the research and prevention of virus mutation, accelerate the research and development of new vaccines and specific drugs".
According to the data released by the joint prevention and control mechanism of the State Council, as of February 18, 2022, nearly 13% of China's total vaccination of the new crown vaccine has not been completed. Vaccination enhancement still needs to be popularized. New vaccines may be needed for new crown virus variants. Existing new crown pneumonia patients are in urgent need of effective therapeutic drugs. As of February 2022, China has exported about 2.1 billion doses of the new crown vaccine to Bangladesh and other places, so the demand at home and abroad remains high.
in the recent years of the outbreak and in anticipation of the normalization of the epidemic,the rise of more and more vaccine companies and the development of new vaccines such as mRNA research and development, it has brought development opportunities and growth opportunities to China's biopharmaceutical industry. It is expected that the vaccine industry will drive upstream suppliers to maintain high growth at a compound growth rate of 23% by 2025.
In-depth implementation of innovation-driven development strategy
report states:"to improve the ability of scientific and technological innovation, increase the incentive of enterprise innovation, and enhance the core competitiveness of manufacturing industry", this includes:"Implement the ten-year plan for basic research, implement the three-year plan for the reform of the scientific and technological system, promote international scientific and technological cooperation, implement tax incentives for enterprises to invest in basic research, promote enterprises to increase R & D investment, and focus on cultivating" specialized and new "enterprises".
The research and development of new drugs in China has mainly gone through four stages: me too, me better, me best and final FIC. According to the Annual Report 2020 on the Current Situation of Clinical Trials for New Drug Registration in China released in November 2021, the drug indications of 9 of the top 10 targets of registered clinical trials are concentrated in the same field, among them, the indications of 7 target drug varieties are concentrated in the anti-tumor field of more than 90%, indicating that the homogenization of biomedical innovation in China is serious. The report guides biopharmaceutical companies to pursue innovative quality and encourages them to invest more in innovative research and development, shifting from cluster me too drugs to me better and FIC drugs.
At present, China's biomedical industry is about to usher in a wave of internationalization. Whether it is the government work report or the 14th five year plan for medical workers, it is proposed to strengthen international cooperation. Enterprises should combine "bringing in" with "going out", and constantly improve their R & D and innovation ability.
at the same time, the upstream raw material consumables of domestic biopharmaceutical companies are facing a neck problem, the report points out."to start the product foundation reengineering project and cultivate specialized new enterprises", this will help to accelerate the domestic substitution of reagent consumables and equipment, which will bring development opportunities for domestic biomedical upstream enterprises and further improve the security of the industrial chain supply chain.
Expanding high-level opening up to the outside world and encouraging foreign investment
report pointed out: "We must actively utilize foreign capital: thoroughly implement the negative list of foreign investment access, expand the scope of encouraging foreign investment, optimize foreign investment promotion services, and promote the construction of free trade zones".the further opening of the Chinese market, it will also provide more opportunities for multinational companies to invest and develop in China, and solve the problems of insufficient local supply capacity and supply stability.
Improve the ability of medical and health services, pay attention to the research of rare disease drugs
report pointed out: "It is necessary to strengthen the supervision of drug quality and safety, gradually improve the level of protection for the prevention and treatment of chronic diseases such as cardiovascular and cerebrovascular diseases, cancer, and infectious diseases such as tuberculosis and hepatitis, and strengthen the research on rare diseases and the guarantee of drug use". It fully reflects the country's emphasis on major diseases and rare diseases. Biopharmaceutical companies should also actively innovate, avoid getting together on the same target and the same track, and pay attention to drug research and development with more clinical value.
-Summary-
the recent epidemic has been repeated, the focus of recent government work has also fallen on the prevention and control of the epidemic. For pharmaceutical companies, actively developing new vaccines and drugs is a good way to solve this problem. For biopharmaceutical upstream companies, Actively realizing independent technological innovation and solving core technologies in key areas of raw materials and equipment is the best policy to adapt to the current market.
